| Market Closed - Nasdaq Other stock markets | 5-day change | 1st Jan Change | ||
| 0.9276 USD | +10.71% |  | +5.41% | +10.63% |
| 12-13 | North American Morning Briefing : Traders Await -2- | DJ |
| 12-12 | B. Riley Downgrades X4 Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $1 From $3 | MT |
March 02, 2022
Share
X4 Pharmaceuticals, Inc. announced that it has entered into a securities purchase agreement with returning investor BCLS II Investco, LP for a private placement of 900,000 shares at a purchase price of $1.80 per share for proceeds of $1,620,000 as well as pre-funded warrants to purchase 766,666 shares of Common Stock at a price of $0.01 per share, at a purchase price of $1.79 per Pre-Funded Warrant for total proceeds of $2,992,332.14 on March 3, 2022. The Pre-Funded Warrants are exercisable at any time after their original issuance and will not expire. The transaction is expected to close on or about March 7, 2022.
Share
© S&P Capital IQ - 2022
Latest news about X4 Pharmaceuticals, Inc.
| North American Morning Briefing : Traders Await -2- | DJ | |
| B. Riley Downgrades X4 Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $1 From $3 | MT | |
| X4 Pharmaceuticals, Inc. Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023 | CI | |
| Transcript : X4 Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 09, 2023 | ||
| X4 Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI | |
| North American Morning Briefing : Traders Await -2- | DJ | |
| X4 Pharmaceuticals Insider Sold Shares Worth $181,573, According to a Recent SEC Filing | MT | |
| X4 Pharmaceuticals Insider Sold Shares Worth $168,371, According to a Recent SEC Filing | MT | |
| X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in Whim Syndrome | CI | |
| X4 Pharmaceuticals Announces Appoints Veteran R. Keith Woods to Board of Directors | CI | |
| Transcript : X4 Pharmaceuticals, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-13-2023 07:30 AM | ||
| X4 Pharmaceuticals Submits NDA to FDA for Mavorixafor to Treat WHIM Syndrome | MT | |
| X4 Pharmaceuticals Announces Submission of New Drug Application to U.S. Fda for Mavorixafor in Whim Syndrome | CI | |
| B. Riley Trims X4 Pharmaceuticals' Price Target to $3 From $4, Keeps Buy Rating | MT | |
| X4 Pharmaceuticals Files $300 Million Mixed Shelf | MT | |
| Transcript : X4 Pharmaceuticals, Inc., Q2 2023 Earnings Call, Aug 10, 2023 | ||
| X4 Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 | CI | |
| North American Morning Briefing : Attention Turns -2- | DJ | |
| X4 Pharmaceuticals, Inc. Announces Appointment of Dr. Christophe Arbet-Engels to Join as Chief Medical Officer | CI | |
| X4 Pharmaceuticals Closes $115 Million Loan Facility with Hercules Capital | CI | |
| X4 Pharmaceuticals, Inc. announced that it expects to receive $115 million in funding | CI | |
| X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) added to Russell Small Cap Comp Value Index | CI | |
| X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) added to Russell 3000 Index | CI | |
| X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) added to Russell 3000E Growth Index | CI | |
| X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) added to Russell 3000E Index | CI |
Chart X4 Pharmaceuticals, Inc.
More charts
Company Profile
X4 Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery and development of therapies for people with diseases of the immune system. Its lead product candidate, mavorixafor, a small molecule antagonist of chemokine receptor C-X-C receptor type 4 (CXCR4), is being developed as an oral, once-daily therapy. Mavorixafor has the potential to provide therapeutic benefit across a variety of chronic neutropenic disorders, including warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, a rare primary immunodeficiency. It also has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
Sector
Calendar
20/03/2024 - Q4 2023 Earnings Release
Related indices
Russell 2000
More about the company
Income Statement Evolution
More financial data
Ratings for X4 Pharmaceuticals, Inc.
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.9276USD
Average target price
3.264USD
Spread / Average Target
+251.91%
Consensus
EPS Revisions
Estimates Revisions
Quarterly earnings - Rate of surprise
Company calendar
| 1st Jan change | Capi. | |
|---|---|---|
X4 PHARMACEUTICALS, INC. | +10.63% | 155M |
IQVIA HOLDINGS INC. | +9.22% | 46B |
LONZA GROUP AG | +34.01% | 39.85B |
MODERNA, INC. | +4.42% | 39.76B |
CELLTRION, INC. | -10.27% | 28.16B |
ICON PUBLIC LIMITED COMPANY | +18.26% | 27.62B |
ALNYLAM PHARMACEUTICALS, INC. | -22.02% | 18.8B |
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | +9.55% | 13.3B |
MEDPACE HOLDINGS, INC. | +29.44% | 12.2B |
BIO-TECHNE CORPORATION | -6.01% | 11.4B |
- Stock
- Equities
- Stock X4 Pharmaceuticals, Inc. - Nasdaq
- News X4 Pharmaceuticals, Inc.
- X4 Pharmaceuticals, Inc. announced that it expects to receive $2.992332 million in funding from BCLS II Investco, LP
